A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: tell (481), recount (1), relay (16), transmit (28), communicate (148), connect (209)

Atezolizumab

Description
Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab Regimen • Bladder – Atezolizumab Indication • The treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description
Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

Nivolumab (lymphoma)

Description
Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating relapsed or refractory classical Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

Nivolumab 240mg (lymphoma)

Description
Chemotherapy Protocol LYMPHOMA Nivolumab (240mg-14 days) Regimen • Lymphoma – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended as an option for
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab-240mg.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

Papers Trust Board - 11 November 2025

Description
Date Time Location Chair Agenda Trust Board – Open Session 11/11/2025 9:00 - 13:00 Conference Room, Heartbeat Education Centre
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-11-November-2025.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description
Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Indication • Isatuximab is indicated where; - the patient has
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

BEACON protocol v8.0 07Mar2023 signed

Description
A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

PV-CHP Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-POLATUZUMAB VEDOTIN-PREDNISOLONE- RITUXIMAB Regimen • Lymphoma – Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone – rituximab Indication • Previously untreated diffuse
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/PV-CHP-Cyclophosphamide-doxorubicin-polatuzumab-vedotin-prednisolone.pdf

Nordic 3000

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-CYTARABINE-DOXORUBICIN-PREDNISOLONE-RITUXIMABVINCRISTINE (Nordic 3000) Inpatient-Outpatient Regimen There are multiple versions of this protocol in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nordic-3000.pdf
41 to 50 of 736
Previous … 3 4 5 6 7 … Next